All In Biotech

Drug Trial Radar · NCT05893862

A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)

A Double-Blind, Cross-Over Placebo-Controlled and Active-Controlled Trial To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia

Last checked: Nov 20, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 107 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

107

Actual

Start

Jun 26, 2023

Primary completion

Feb 22, 2024

Study completion Feb 22, 2024

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jun 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study to evaluate the effect of a supratherapeutic dose of 80 mg elpipodect on the QT interval corrected for heart rate (QTc interval) and to assess the safety and tolerability of multiple once-daily doses of elpipodect in participants with schizophrenia. The effects of 3 treatment sequences 1) elpipodect (48 mg \[Day 1\] and 80 mg \[Day2\]); 2) standard image placebo (Day 1) and moxifloxacin 400 mg (Day 2); and 3) elpipodect placebo (Day 1 and Day 2) were assessed with 5-day washout intervening sequence. Participants received all treatments in a counter-balanced order according to 1 of 6 possible treatment sequences. The primary hypothesis is that the administration of an 80 mg elpipodect dose on Day 2 does not prolong the QTc interval to a clinically significant degree. Specifically, the true mean difference (elpipodect - placebo) in QTc change from baseline is less than 10 milliseconds (msec).

Conditions

  • Schizophrenia

Interventions

  • ElpipodectDrug

    Oral Tablet

  • MoxifloxacinDrug

    Oral Tablet

  • PlaceboDrug

    Oral Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in QT Interval Corrected for Heart Rate (QTc) Following MK-8189 TreatmentTime frame: Day 1 (MK-8189 48 mg and placebo) and Day 2 (MK-8189 80 mg and placebo)
  2. Number of Participants With Adverse Events (AEs)Time frame: Up to ~30 days after each dose
  3. Number of Participants Discontinuing Study Therapy Due to AETime frame: Up to ~30 days after each dose

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • California Clinical Trials Medical Group managed by PAREXEL-PAREXEL International ( Site 0003)

    Glendale, California

  • NRC Research Institute ( Site 0004)

    Orange, California

  • Velocity Clinical Research, Hallandale Beach ( Site 0002)

    Hallandale, Florida

  • Hassman Research Institute Marlton Site ( Site 0001)

    Marlton, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.